All News

Patients and caregivers can only make truly informed decisions about end-of-life care when they understand the natural process of dying, says Tani Bahti, RN.

Trained therapy animals help patients relieve stress and anxiety during treatment.

Data from the phase 3 EMILIA trial shows progression-free survival benefit in metastatic HER2-positive breast cancer patients.

Two new targeted therapies, which each focus on a different way to block cancer growth signaling, delayed disease progression in advanced melanoma patients.

A new drug regimen that combines Treanda (bendamustine) and Rituxan (rituximab) has been shown to more than double progression-free survival time.

Afatinib significantly improves progression-free survival among patients with advanced lung cancer that harbors certain genetic mutations compared with standard chemotherapy.

To tackle platinum-resistant ovarian cancer, a French research group added Avastin (bevacizumab) to standard chemotherapy.

Patients with anaplastic oligodendroglial tumors harboring certain chromosomal deletions have a reduced risk of dying after receiving radiation and chemotherapy.

Patients who experience chemotherapy-induced peripheral neuropathy may find relief with the antidepressant Cymbalta.

Men with metastatic prostate cancer lived longer with continuous hormone therapy compared with intermittent therapy.

Regorafenib, which targets two cancer cell pathways, extended survival in both cancers in two separate studies for GIST and metastatic colorectal cancer.